Literature DB >> 23503553

Clinical response to thalidomide in the treatment of intracranial tuberculomas: case report.

Patricia de la Riva1, Miguel Urtasun, Tamara Castillo-Trivino, Xabier Camino, Maialen Arruti, Elisabet Mondragón, Adolfo Lopez de Munain.   

Abstract

We describe a patient with multiple intracranial tuberculomas resistant to standard care with antituberculosis drugs and corticosteroids who responded well to thalidomide. Adjunctive thalidomide may have a role in the management of refractory intracranial tuberculomas, although it should be used conservatively owing to its potential adverse events.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23503553     DOI： 10.1097/WNF.0b013e318285caa1

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  4 in total

Review 1.  Treatment of Tuberculous Meningitis and Its Complications in Adults.

Authors:  Angharad Davis; Graeme Meintjes; Robert J Wilkinson
Journal:  Curr Treat Options Neurol       Date:  2018-02-28       Impact factor: 3.598

2.  Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: A case report.

Authors:  Emanuela Caraffa; Gianluca Russo; Serena Vita; Miriam Lichtner; Anna Paola Massetti; Claudio Maria Mastroianni; Vincenzo Vullo; Maria Rosa Ciardi; Camilla Ajassa
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

3.  Thalidomide in the treatment of human immunodeficiency virus-negative tuberculous meningitis: A case report.

Authors:  Ping Liu; Ning Pei; Xuhui Liu; Wei Huang; Shuihua Lu
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

Review 4.  Tumor necrosis factor antagonists for paradoxical inflammatory reactions in the central nervous system tuberculosis: Case report and review.

Authors:  Miguel Santin; Cristina Escrich; Carles Majòs; Mariona Llaberia; Maria D Grijota; Imma Grau
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.